TP53 and neoplasm: Our TP53 mutation frequency of 54.5% dropped to 40% when analyses were confined exclusively to primary tumor samples (FFPE), close to the frequency (TP53, 46%; KRAS 25%) in a Finnish study of 425 FFPE samples.47